A new facility in Japan for the production of autologous induced pluripotent stem cells (iPSCs) may help drive national R&D activities in the autologous cell therapy area by reducing both safety risks and costs, the country’s leading research foundation in the field is predicting.
Receiving a donation totaling JPY4.5bn ($30m) from the country’s richest individual, the new facility is hopeful it can reduce production...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?